诺和诺德候任CEO：将关注公司的成本基数

Core Insights - The incoming CEO Mike Doustdar emphasizes the need to focus on the company's cost base after a period of "rapid growth" [2] - The company may need to reallocate certain resources but has not yet provided specific cost-cutting measures [2] - The company possesses the best pipeline in the weight loss drug sector but acknowledges the need for improvement [2]